119892-48-7

Upstream product

• 124831-36-3 N-[(2R,3S)-2-(2-Furan-2-yl-ethyl)-4-oxo-azetidin-3-yl]-2-phenoxy-acetamide 
• 99333-65-0 1-benzyl-3β-((S)-2-oxo-4-phenyloxazolidin-3-yl)-4β-[2-(2-furyl)ethyl]azetidin-2-one 
• 79791-38-1 4-dodecylbenzenesulphonyl azide 
• 124831-38-5 cis-β,4-dioxo-3-[(phenoxyacetyl)amino]-2-azetidinepentanoic acid, (4-nitrophenyl)methyl ester 
• 124831-37-4 cis-4-oxo-3-[(phenoxyacetyl)amino]-2-azetidinepropanoic acid 

Downstream Products

• 124831-39-6 (6R,7S)-3-Chloro-7-[(R)-2-((E)-2-methoxycarbonyl-1-methyl-vinylamino)-2-phenyl-acetylamino]-8-oxo-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 4-nitro-benzyl ester 
• 76470-66-1 loracarbef 
• 123932-46-7 carbacephalosporin hydrochloride 
• 119892-46-5 p-nitrobenzyl 7β-[(phenoxyacetyl)amino]-3-hydroxy-1-carba-1-dethia-3-cephem-4-carboxylate 

Relevant academic research and scientific papers

AN ENANTIOSELECTIVE SYNTHESIS OF LORACARBEF (LY163892/KT3777)

An enantioselective synthesis of the new, orally absorbable, totally synthetic β-lactam antibiotic, loracarbef(LY163892/KT3777) is described.

Process for intermediates to 1-carba(1-dethia)-3-cephem-4-carboxylic acids

The present invention provides a process for preparing α-diazo-β-keto ester intermediates to 1--carba(1-dethia)-3-cephem-4-carboxylic acids.